INTERCEPT-Cryoprecipitation
  • Home
  • Resources
    • Resources
    • FDA Approval Press Release
  • About Cerus
    • About Cerus
    • Careers
Select Page
  • Home
  • Resources
    • Resources
    • FDA Approval Press Release
  • About Cerus
    • About Cerus
    • Careers
Cerus Websites
  • Cerus.com
  • INTERCEPT-USA.com
  • HCP.INTERCEPT-USA.com
  • INTERCEPT-Canada.com
  • INTERCEPTBloodSystem.com
  • INTERCEPT-Cryoprecipitation.com
  • Cerus.com

    The corporate website includes broad information about Cerus, resources for investors, and career opportunities.
  • INTERCEPT-USA.com

    For residents of the United States – Blood centers and transfusion services will find topics related to the production of pathogen reduced products.
  • HCP.INTERCEPT-USA.com

    For residents of the United States – Hospital blood banks and healthcare practitioners will find content related to clinical topics, implementation, and education.
  • INTERCEPT-Canada.com

    For residents of Canada – Specific information for pathogen reduced platelets and plasma including package inserts.
  • INTERCEPTBloodSystem.com

    Visitors in Europe, the Middle East, Africa, Asia or Latin America will find information about pathogen inactivated platelets and plasma.
  • INTERCEPT-Cryoprecipitation.com

    For residents of the United States – Learn more about the INTERCEPT® Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex.

Resources

  • Product Information
  • Package Inserts

Press Releases:

11.30.2020 - Cerus Corporation Announces FDA Approval for INTERCEPT Blood System for Cryoprecipitation
10.31.2018 - Cerus Receives FDA Breakthrough Device Designation for Pathogen-Reduced Cryoprecipitate

Pathogen Reduced Cryoprecipitated Fibrinogen Complex Product Brochure

Download View

Pathogen Reduced Cryoprecipitated Fibrinogen Complex Package Insert

Download View

Pathogen Reduced Plasma, Cryoprecipitate Reduced Package Insert

Download View

Global Headquarters

1220 Concord Avenue
Concord, CA US 94520
+1 925.288.6000

Rx only.
See Package Insert for full prescribing information, including Contraindications, Warnings and Precautions There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process. For a full list of pathogens, please refer to Package Insert.

LinkedIn
  • Cookie Policy and Tracking Opt-out Guide
  • Legal
  • Privacy Policy
Copyright (c) 2020 Cerus Corporation. INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation.
Contraindications, Warnings and Precautions
INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex:
CONTRAINDICATIONS

Contraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.

Contraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS AND PRECAUTIONS

Only the INTERCEPT Blood System for Cryoprecipitation is approved for use to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex.

For management of patients with vWD or factor XIII deficiency, Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used if recombinant or specific virally-inactivated factor preparations are available. In emergent situations, if recombinant or specific virally-inactivated factor preparations are not available, Pathogen Reduced Cryoprecipitated Fibrinogen Complex may be administered.

By continuing to use this website, you agree to the use of cookies described in our Cookies Policy.

OK